



New Drug

Ferric Maltol (Accrufer)

Why it matters:



Ferric maltol is the first oral iron supplement for adults with iron deficiency that requires a prescription.

What else to know:



It avoids stomach absorption since it's bound to maltol, a natural sugar, that breaks down in the small intestine rather than the stomach. This may improve absorption and help improve iron stores in patients with inflammatory bowel disease (IBD) and chronic kidney disease, who typically have anemia and a poor response to most oral iron supplements.

Manufacturer	Kye Pharmaceuticals Inc.
Approved use	Iron deficiency anemia in adult patients who are unresponsive or intolerant to other oral iron preparations.
Approval date	August 21, 2024
Anticipated availability	First quarter 2025
Dosage and administration	30 mg po bid, morning and evening, on an empty stomach.
Storage requirements	Room temperature at 15°C to 30°C
Prescribing information	Ferric Maltol Product Monograph





New Drug

Ferric Maltol (Accrufer)

References:

- Khoury A, Pagan KA, Farland MZ. Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults. *Ann Pharmacother.* 2021 Feb;55(2):222-229.
- Schmidt C, Allen S, Kopyt N, Pergola P. Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion. *J Clin Med.* 2021 Sep 28;10(19):4448.
- Pantopoulos K. Oral iron supplementation: new formulations, old questions. *Haematologica.* 2024 Sep 1;109(9):2790-2801.

Users of this resource are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.

Copyright © 2025 by Therapeutic Research Center. All Rights Reserved. trchealthcare.com



Article, *Get the Scoop on Ferric Maltol for Iron Deficiency. Pharmacist's Letter/Pharmacy Technician's Letter/Prescriber Insights.* March 2025. [410366]. For nearly 40 years, our editors have distilled primary literature into unbiased, evidence-based recommendations with 0% pharma sponsorship. [Learn more](#)